Evidence map›Paper›PMID 39585568›Full record

ArticleAnnals of nuclear medicine2025

Improvement of tumor-to-blood ratio of radioimmunoconjugates by poly(ethyleneimine)-containing chelating agent.

Kazuma Nakashima, Hiroki Shimohara, Hiroyuki Watanabe, Masahiro Ono

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Kazuma Nakashima *Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto, 606-8501, Japan.
Hiroki Shimohara *Department of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto, 606-8501, Japan.
Hiroyuki WatanabeDepartment of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto, 606-8501, Japan.
Masahiro OnoDepartment of Patho-Functional Bioanalysis, Graduate School of Pharmaceutical Sciences, Kyoto University, 46-29 Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto, 606-8501, Japan. ono@pharm.kyoto-u.ac.jp.ORCID http://orcid.org/0000-0002-2497-039X

Funding

AMED JP23ae0121010AMED JP24ae0121010
6 · The paper itself

Abstract

objectiveMonoclonal antibody (mAb)-based radioimmunoconjugates (RICs) exhibit marked tumor uptake in cancer imaging and therapy, although their high blood retention has limited the development of RICs. In our previous study, a trifunctional chelating agent with a cationic poly(ethyleneimine) (PEI) structure of tetraethylenepentamine (PEI4), maleimide-DOTA-PEI4 (MDI4), improved the tumor-to-blood ratio of RICs by increasing tumor retention compared with a conventional bifunctional chelating agent. In this study, we developed a novel chelating agent composed of a maleimide moiety, DOTA derivative, and two PEI4 structures as a PEI4-2 unit, maleimide-DOTA-PEI4-2 (MDI4-2), a design for a highly cationized chelating agent to synthesize RICs. The properties of MDI4-2 were compared with MDI4 to evaluate the effect of the PEI4-2 unit on the pharmacokinetics of RICs.

methodsTrastuzumab and

results[

conclusionMDI4-2 with the PEI4-2 unit exhibited favorable properties for designing RICs with an improved tumor-to-blood ratio.

Indexed as

Chelating AgentsImmunoconjugatesPolyethyleneimineAnimalsCell Line, TumorFemaleHeterocyclic Compounds, 1-RingHumansIndium RadioisotopesMiceTissue DistributionChelating AgentsHeterocyclic Compounds, 1-RingImmunoconjugatesIndium RadioisotopesPolyethyleneimineCationizationPoly(ethyleneimine) (PEI)Radioimmunoconjugate (RIC)Residualizing propertyTumor-to-blood ratio

Identifiers

PMID39585568

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.